What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Disease
- Cancer
His primary areas of investigation include Internal medicine, Ulcerative colitis, Crohn's disease, Gastroenterology and Surgery.
Much of his study explores Internal medicine relationship to Physical therapy.
His Ulcerative colitis research integrates issues from Endoscopy, Colitis and Inflammatory bowel disease.
His Crohn's disease study contributes to a more complete understanding of Disease.
His research in Gastroenterology intersects with topics in SF-36, Granulocyte, Double blind and Monocyte.
The study incorporates disciplines such as Placebo, Infliximab and Cohort in addition to Surgery.
His most cited work include:
- Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis (2790 citations)
- Infliximab for the treatment of fistulas in patients with Crohn's disease. (2257 citations)
- Infliximab Maintenance Therapy for Fistulizing Crohn's Disease (1693 citations)
What are the main themes of his work throughout his whole career to date?
The scientist’s investigation covers issues in Internal medicine, Ulcerative colitis, Gastroenterology, Crohn's disease and Inflammatory bowel disease.
His Internal medicine study incorporates themes from Placebo and Surgery.
His Ulcerative colitis study combines topics in areas such as Tofacitinib, Colitis, Clinical trial, Adverse effect and Maintenance therapy.
His Gastroenterology study which covers Infliximab that intersects with Adalimumab.
His Crohn's disease research is within the category of Disease.
His Inflammatory bowel disease research incorporates elements of Quality of life, Immunology, Intensive care medicine, Physical therapy and Cohort.
He most often published in these fields:
- Internal medicine (64.62%)
- Ulcerative colitis (40.31%)
- Gastroenterology (37.23%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (64.62%)
- Ulcerative colitis (40.31%)
- Gastroenterology (37.23%)
In recent papers he was focusing on the following fields of study:
Bruce E. Sands mostly deals with Internal medicine, Ulcerative colitis, Gastroenterology, Crohn's disease and Ustekinumab.
Many of his research projects under Internal medicine are closely connected to In patient with In patient, tying the diverse disciplines of science together.
His biological study spans a wide range of topics, including Placebo and Hazard ratio.
His Ulcerative colitis study combines topics from a wide range of disciplines, such as Tofacitinib, Colitis, Immunology, Calprotectin and Randomization.
His Gastroenterology research incorporates themes from C-reactive protein, Phases of clinical research and Inflammatory biomarkers.
Crohn's disease is a subfield of Disease that Bruce E. Sands tackles.
Between 2018 and 2021, his most popular works were:
- Microbiotas from Humans with Inflammatory Bowel Disease Alter the Balance of Gut Th17 and RORγt+ Regulatory T Cells and Exacerbate Colitis in Mice. (122 citations)
- Safety of Tofacitinib for Treatment of Ulcerative Colitis, Based on 4.4 Years of Data From Global Clinical Trials. (84 citations)
- Venous thromboembolic events in the tofacitinib ulcerative colitis clinical development programme. (57 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Disease
- Cancer
Internal medicine, Ulcerative colitis, Crohn's disease, Inflammatory bowel disease and Gastroenterology are his primary areas of study.
His Placebo research extends to the thematically linked field of Internal medicine.
The concepts of his Ulcerative colitis study are interwoven with issues in Tofacitinib, Colitis, Clinical trial, Maintenance therapy and Calprotectin.
Bruce E. Sands has included themes like Surgery and Anastomosis in his Crohn's disease study.
His Inflammatory bowel disease research includes elements of Physical therapy, Quality of life and Intensive care medicine.
As a part of the same scientific family, Bruce E. Sands mostly works in the field of Gastroenterology, focusing on Phases of clinical research and, on occasion, Mucosal healing and Blinded study.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
